{"id":4391,"date":"2018-12-04T00:14:32","date_gmt":"2018-12-03T23:14:32","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4391"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"positive-stellungnahme-der-ema-zu-srk-015","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/positive-stellungnahme-der-ema-zu-srk-015\/","title":{"rendered":"Positive Stellungnahme der EMA zu SRK-015"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;Wir freuen uns \u00fcber die positive Stellungnahme der EMA COMP f\u00fcr den Orphan-Drug-Status von SRK-015, die einen weiteren wichtigen Meilenstein f\u00fcr dieses klinische Programm darstellt&#8221;, sagte Nagesh Mahanthappa, PhD, Pr\u00e4sident und CEO von Scholar Rock. &#8220;Wir glauben, dass SRK-015 das Potenzial hat, die erste muskelgesteuerte Therapie zur Verbesserung der Muskelfunktion bei Patienten mit SMA zu sein, und freuen uns auf die Zusammenarbeit mit der EMA, w\u00e4hrend wir das Programm vorantreiben, einschlie\u00dflich unserer Absicht, im ersten Quartal 2019 eine Proof-of-Concept-Studie der Phase 2 einzuleiten&#8221;<\/p>\n<cite>https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-announces-positive-opinion-european-medicines<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Wir freuen uns \u00fcber die positive Stellungnahme der EMA COMP f\u00fcr den Orphan-Drug-Status von SRK-015, die einen weiteren wichtigen Meilenstein f\u00fcr dieses klinische Programm darstellt&#8221;, sagte Nagesh Mahanthappa, PhD, Pr\u00e4sident und CEO von Scholar Rock. &#8220;Wir glauben, dass SRK-015 das Potenzial hat, die erste muskelgesteuerte Therapie zur Verbesserung der Muskelfunktion bei Patienten mit SMA zu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4391","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4391"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4391\/revisions"}],"predecessor-version":[{"id":39885,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4391\/revisions\/39885"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}